← All trials
NCT03387774
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2018
- Primary completion
- Aug 30, 2018
- Completion date
- Nov 30, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 176
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityCollaborator
- First People's Hospital of FoshanCollaborator
- Guangzhou Medical UniversityCollaborator
- People's Hospital of ZhongshanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.